Novel Rinse to Treat Oral Candidiasis in Cancer Patients

治疗癌症患者口腔念珠菌病的新型漱口水

• 批准号: 6989894
• 负责人: Charles J Gauntt
• 金额: $ 15.95万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-02 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6989894
• 关键词: Candida; Candida albicans; antiinfective agents; biofilm; cancer complication; candidiasis; drug adverse effect; drug design /synthesis /production; drug screening /evaluation; laboratory rat; local antiinfective agents; microorganism disease chemotherapy; mouthwash; nonhuman therapy evaluation; opportunistic infections; oral health

DESCRIPTION (provided by applicant): The goal of this project is to develop a unique, safe and efficacious mouth rinse to treat oral candidiasis in patients with cancer. Oral candidiasis or oral thrush is a disease caused by all species of the fungus Candida and is a common infection for immunosuppressed individuals, particularly cancer patients. If not blunted, oral candidiasis can transit to esophageal candidiasis or life-threatening candidemia. The majority of cells of most Candida sp. exist in the oral cavity in a unique ecologic community known as a biofilm. Cells in the encased setting of biofilms are far more resistant to antifungal mouth rinses and drugs than free-living unattached Candida, thus compromising the effectiveness of treatment. In addition, the most effective mouth rinses have several risks and adverse side effects, including induction of potential allergies, exacerbation of periodontitis, increasing tartar on teeth, erosion of enamel and altering of the appreciation for foods. In previous work, Biomedical Development Corporation has developed locide(r), a safe and efficacious broad-spectrum antimicrobial that has been demonstrated to be effective in the presence of biofilm. The objective of this Phase I project is to demonstrate the feasibility of using locide as a mouth rinse for the treatment of oral candidiasis in cancer patients. To achieve this goal, the following Specific Aims will be executed: Specific Aim 1. Optimize locide Formulation for Use in Treating Oral Candidiasis Specific Aim 2. Demonstrate the Effectiveness of locide in Killing Candida albicans and Mixed Candida sp. Cells in Biofilms Specific Aim 3. Demonstrate Safety of locide Formulations

描述（由申请人提供）： 该项目的目的是开发一种独特，安全和有效的口冲洗，以治疗癌症患者的口腔念珠菌病。口服念珠菌病或口腔鹅口疮是由所有真菌念珠菌引起的疾病，是免疫抑制个体（尤其是癌症患者）的常见感染。如果不钝化，口服念珠菌病可以转移到食管念珠菌病或威胁生命的念珠菌病。大多数念珠菌的大多数细胞。在一个被称为生物膜的独特生态界的口腔中存在。与自由活动的非附着的念珠菌相比，在包裹的生物膜环境中，对抗真菌口腔冲洗和药物的耐药性更大，从而损害了治疗的有效性。此外，最有效的口腔冲洗有几种风险和不利的副作用，包括诱导潜在的过敏，加剧牙周炎，牙齿上的牙垢增加，搪瓷的侵蚀以及对食物的欣赏。 在先前的工作中，生物医学开发公司开发了位置（R），这是一种安全有效的广谱抗菌剂，已被证明在存在生物膜的情况下是有效的。该阶段I项目的目的是证明将位置用作癌症患者口服念珠菌病的口腔冲洗的可行性。为了实现这一目标，将执行以下特定目标： 特定目标1.优化用于治疗口服念珠菌病的位置公式 具体目的2。证明位置在杀死白色念珠菌和混合念珠菌sp中的有效性。生物膜中的细胞 特定目的3。证明位置配方的安全性